[HTML][HTML] Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal

P Valent, C Akin, K Hartmann, I Alvarez-Twose… - …, 2021 - journals.lww.com
Mastocytosis is a hematologic neoplasm characterized by expansion and focal
accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone …

Advances in the classification and treatment of mastocytosis: current status and outlook toward the future

P Valent, C Akin, K Hartmann, G Nilsson, A Reiter… - Cancer research, 2017 - AACR
Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the
expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The …

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

DJ DeAngelo, DH Radia, TI George, WA Robinson… - Nature medicine, 2021 - nature.com
Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT
D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) …

New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

A Reiter, TI George, J Gotlib - … Journal of the American Society of …, 2020 - ashpublications.org
Systemic mastocytosis (SM) has greatly benefited from the broad application of precision
medicine techniques to hematolymphoid neoplasms. Sensitive detection of the recurrent KIT …

[HTML][HTML] Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice

P Valent, K Hartmann, J Schwaab… - The Journal of Allergy …, 2022 - Elsevier
Mastocytosis is a myeloid neoplasm defined by expansion and focal accumulation of clonal
mast cells (MCs) in one or more organs. The disease exhibits a complex pathology and may …

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

A Reiter, J Gotlib, I Álvarez-Twose, DH Radia, J Lübke… - Leukemia, 2022 - nature.com
Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor
overall survival (OS). This study (NCT04695431) compared clinical outcomes between …

Mast cells as drivers of disease and therapeutic targets

F Siebenhaar, FA Redegeld, SC Bischoff, BF Gibbs… - Trends in …, 2018 - cell.com
Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-
driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune …

Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?

C Akin, M Arock, P Valent - Journal of Allergy and Clinical Immunology, 2022 - Elsevier
Indolent systemic mastocytosis (ISM) is the most prevalent form of systemic mastocytosis.
Many patients with ISM suffer from mast cell (MC) mediator-related symptoms. In a small …

[HTML][HTML] Novel strategies to target mast cells in disease

A Paivandy, G Pejler - Journal of Innate Immunity, 2021 - karger.com
Mast cells (MCs) are versatile effector cells of the immune system, characterized by a large
content of secretory granules containing a variety of inflammatory mediators. They are …

Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches

P Valent, C Akin, KV Gleixner, WR Sperr… - International journal of …, 2019 - mdpi.com
Mastocytosis is a hematopoietic neoplasm defined by abnormal expansion and focal
accumulation of clonal tissue mast cells in various organ-systems. The disease exhibits a …